TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia
TG Therapeutics has initiated a Phase 2 clinical trial evaluating BRIUMVI (ublituximab-xiiy) in adults with treatment-resistant schizophrenia. The open-label study will enroll approximately 60 patients receiving standard-of-care antipsychotics, with the primary endpoint measuring a 20% reduction in PANSS total score at Week 12.
Key figures
- Drug Name
- BRIUMVI (ublituximab-xiiy)
- Phase Of Trial
- Phase 2
- Indication
- treatment-resistant schizophrenia
- Patient count
- 60
- Primary endpoint
- 20% reduction in PANSS total score at Week 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.